Drug Profile

HX 035

Alternative Names: HX-035

Latest Information Update: 04 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator HanX Biopharmaceuticals
Class Anti-inflammatories; Bispecific antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders; Inflammation

Most Recent Events

19 May 2025 HanX Biopharmaceuticals announces intention to submit an Investigation New Drug application for Inflammation and Autoimmune disorders by the first quarter of 2026
19 May 2025 Pharmacodynamics and pharmacokinetics data from a preclinical study released by HanX Biopharmaceuticals
07 May 2025 Hanx Biopharmaceuticals has patent protection for HX 035 globally (prior to May 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com